Generic Firms Get Supreme Shield From Product Liability, But Court Hints At Reg Change
This article was originally published in The Pink Sheet Daily
Executive Summary
In Pliva v. Mensing, the high court said it was impossible for generic manufacturers to comply with both state tort laws and FDA regulations requiring them to have the same labels as those for brand name counterparts.
You may also be interested in...
FDA’s New Category For Pre-1984 ANDAs May Impact Patent Exclusivity, Product Liability
The agency aims to treat ANDAs approved prior to enactment of the Hatch-Waxman amendments, dubbed PANDAs, as 505(b) NDAs. The goal is to make it easier to designate products as reference listed drugs, but experts say it effectively turns ANDA holders into NDA holders, which could have implications for label changes, patent listings, and product liability litigation.
Brand-Name Drug Makers' Duty To Warn Extends After Product Sale To Another Company
California Supreme Court finds Novartis liable for alleged injuries from use of a generic version of Brethine even though they occurred six years after Novartis transferred the NDA; dissenting opinion says this will expose companies to "liability in perpetuity."
Brand-Name Drug Makers' Duty To Warn Extends After Product Sale To Another Company
California Supreme Court finds Novartis liable for alleged injuries from use of a generic version of Brethine even though they occurred six years after Novartis transferred the NDA; dissenting opinion says this will expose companies to "liability in perpetuity."